This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

It sounds like the tail end of a pharmaceutical commercial: "A month's supply of insulin could cost as little as $35." But that's the deal New Mexico Attorney General Raúl Torrez is poised to maintain ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

DEPARTMENT OF JUSTICE NEWS RELEASE Attorney General Raúl Torrez announced settlements with two major insulin ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

Novo Nordisk accounts for 34% of the global diabetes ... qualities that it shares with the only two other global insulin players, Sanofi and Eli Lilly. However, we don't think Novo's cost ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...